Table 1 Characteristics included comparative studies, patient demographics, ERP versus ERAS, and outcomes
Author/year | Nr patients (I1/C2) | Intervention | Control | Primary LOS (I1/C2) | Total LOS (1/C2) | Readmissions (1/C2) | Complications (1/C2) | Reoperation (1/C2), n (%) | Mortality (1/C2) | Other |
|---|---|---|---|---|---|---|---|---|---|---|
Bednarski et al. [32]; 2019 | 14/16 | MIS3, ERAS and telemonitoring | ERAS | 27.1/ 51.5 (median; hr) | 28.3/51.5 (median; hr) | 14.3/0% | 35.7/0% | 2/0 (14.3/0) | 0/0 (30 days) | I1: CD4 ≥ III: 2, CD4 I-II: 3 C2: - |
Kiran et al. [28]; 2022 | 87/88 | < 24 h ERP | ERP | 29 pts (33.3%) discharged < 24 h, mean LOS 17.2–109 / 82.3 h | NI8 | 9.2/8% | 24.1/22.7% | 2/0 (3.4/0) | 0/NI8 | I1: 9 blood transfusions, 5 ileus, 3 AL5, 2 SSI6 C2: 9 blood transfusions, 5 ileus, 4 SSI6, 1 AL5 |
Lee et al. [12]; 2022 | 48/73 | SDD7 ERP | ERP | 0/2 (median; days) | NI8 | 6/4% | 17/15% | NI8 | NI8 | I1: 2 SSI6, 2 genitourinary compl., 2 bleeding, 2 other, 1 AL5, 1 cardiopulmonary compl. C2: 4 ileus, 3 AL5, 2 cardiopulmonary compl. 2 genitourinary compl., 1 bleeding, 1 other |
Popeskou et al. [33]; 2022 | 51/782 | ERAS with discharge < 24 h protocol | ERAS | 6% (51) discharged < 24 h | NI8 | 7.8/9.2% | NI8 | 3.9/2.9% | 0/2 (0/0.3%) | I1: 47 of 51 patients had uneventful recoveries |
Tweed et al. [26]; 2022 | 41/74 | 23 h ERP | ERAS | 80% discharge < 24 h | NI8 | 17.1/5.3% | 31.7/26.7% | 4.9/8.0% | 0/0 | I1: 4 bleeding, 4 bladder ret., 2 ileus, 2 infections, 1 AL5, 1 electrolyte deficiency C2: 6 infections, 4 AL5, 2 abscess, 2 anemia, 2 AF9, 2 electrolyte deficiency, 1 bowel ischemia, 1 bladder ret., 1 ileus, 1 tachycardia, 1 embolus |